Business Context and Reporting Period
This Form 8-K was filed by NanoVibronix, Inc. (not Envue Medical, Inc.) on March 29, 2019, reporting events occurring on March 29 and April 1, 2019. The company is an emerging growth company incorporated in Delaware. The filing details the entry into material definitive agreements involving the issuance of convertible promissory notes and warrants to accredited investors.
Key Financial Metrics and Capital Structure
- Debt Issuance: The company issued two convertible promissory notes with a total principal amount of $225,000 ($125,000 on March 29 and $100,000 on April 1).
- Interest Rate: Notes bear interest at 6% per annum, payable on the Maturity Date.
- Warrants Issued: Two seven-year warrants were issued to purchase a total of 90,000 shares (50,000 and 40,000 respectively) of common stock or Series C preferred stock.
- Warrant Exercise Price: The lesser of 80% of the exercise price of warrants in the first subsequent equity financing or $4.80.
- Conversion Price: Upon maturity or qualified financing, conversion is at the lesser of 80% of the qualified financing price (or estimated value per share) or $4.00.
- Liquidity and Cash Flow: The filing text does not provide specific cash flow, liquidity, or working capital figures.
- Revenue and Profit: The filing text does not provide revenue, profit, or margin data.
Material Changes and Terms
The primary material change is the creation of a direct financial obligation and the potential dilution of existing shareholders through the issuance of the Notes and Warrants.
- Maturity Date: The earlier of the 5-year anniversary of issuance or the date the company completes a "Qualified Financing" (aggregate proceeds of at least $2,000,000).
- Conversion Options: Investors may elect to receive cash or shares upon maturity. Upon a Qualified Financing, investors may convert into the same class of equity sold in that financing, Series C preferred stock, or common stock.
- Dilution Cap: The aggregate number of shares issuable upon exercise of Warrants and conversion of Notes cannot exceed 9.9% of the total shares outstanding immediately preceding issuance.
- Beneficial Ownership Limit: Warrant holders cannot exercise if it would result in beneficial ownership exceeding 9.99%.
Outlook, Risks, and Contingencies
The filing indicates the company is actively seeking equity financing, evidenced by the "Qualified Financing" trigger set at $2,000,000. The terms of the notes and warrants are heavily discounted (20% discount) relative to future financing prices, which may signal a need for immediate capital at favorable terms for investors.
- Risk of Dilution: Existing shareholders face potential dilution up to the 9.9% cap if the notes convert or warrants are exercised.
- Contingency: The repayment or conversion of the debt is contingent on the company's ability to raise a Qualified Financing or reach the 5-year maturity date.
- Unregistered Sales: The securities were sold under Section 4(a)(2) and Rule 506 of Regulation D exemptions, meaning they are not registered with the SEC and resale is restricted until a registration statement is effective.
Investor Verification Checklist
- Verify the company's current cash position and runway to determine if the $225,000 raised is sufficient to reach the $2,000,000 Qualified Financing threshold.
- Confirm the current fully diluted share count to calculate the exact dilution impact of the 9.9% cap.
- Review the company's pipeline for upcoming equity financings to assess the likelihood of early conversion of the notes.
- Check for any subsequent filings regarding the status of the Qualified Financing or additional debt issuances.
- Clarify the discrepancy between the requested company name (Envue Medical, Inc.) and the actual registrant (NanoVibronix, Inc.).